$PFENot often you see a weekly chart this clean. This has been the line in the sand for 25yrs. Chart is self explanatory. If you have time and are patient this could be a good R/RLongby SandmanTradeDec 15, 20230
Pfizer. Bad news are coming !?❌💉💉❌As a double top a lot of thinks in my mind. i will update NShortby thanoskUpdated Dec 14, 20234413
Pfizer.... Start buildingPfizer is one of those companies that we all feel has been shady and the stock value shows it. As much as human emotion can draw this value down, hedge funds and smart money will start stepping in now. The chart says it all. We are talking about one of the longest running publically traded companies folks, this will rebound. Its not a matter of if, but when. I have started a minor position in Pfizer today and plan to DCA weekly small amount until we form a bullish trend. Good luck!NLongby farmtrader15Updated Dec 13, 2023113
PFE - BULLISH SCENARIOPfizer (NYSE:PFE) gained EU antitrust approval for its $43 billion acquisition of Seagen, a cancer drug maker. This acquisition, announced in March, is Pfizer's largest recent purchase, fueled by the financial success of its COVID-19 vaccines and treatments. The European Commission found no significant competition or pricing concerns in the 27-country European Union, stating that the merger doesn't raise competition issues. Seagen, based in Washington, specializes in antibody-drug conjugates designed to selectively destroy cancer cells, sparing healthy ones. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses. NLongby legacyFXofficialOct 19, 2023119
Pfizer (NYSE: $PFE) Stock SinksKey Takeaway 1. Shares of Pfizer tanked Wednesday as investors digested the subpar guidance, falling as much as 9% to below $26 in morning trading, hitting their lowest intraday share price since 2013. That’s the largest single-day drop for Pfizer since January 2009. 2. Pfizer said Wednesday it expects 2024 revenue to come in between $58.5 billion and $61.5 billion, representing roughly zero growth from 2023’s forecasts and coming in well below analysts’ average 2024 projected sales of $62.6 billion, according to FactSet. 3. Notably, Pfizer said it expects 2024 sales for its Covid products—Paxlovid pills and the Comirnaty vaccine—to be about $8 billion, a nearly 90% drop from the roughly $57 billion of revenue its Covid series brought in last year. NShortby DEXWireNewsDec 13, 20232
PFE updateThis scenario is what i am looking for, reclaim yellow line above and most likely this set-up gets invalidated. Until then, patience is needed. NLongby BlaircatsUpdated Dec 13, 2023113
PFERisk and reward... Oversold here severely at 26$ support. This is a long term investment idea .. I think Pfe will retrace back to mid 30's by next year.. Pfe is back to feb 2020 covid crash levels. 26$ support has held for over a decade. NLongby ContraryTraderDec 13, 2023229
Pfizer P/E tied to decline; strong dividend option?Pfizer has an extensive history of high dividend yield: 5.73% TTM, up significantly since the sharp 2020-2021 decline--payout ratio 90.08%. However, a significant decline in earnings is tied directly to a share price decline. Unsure if recovery is expected, good horizons: approval in EU (small) } Bad horizons: Pfizer's uncontested market share/exclusivity decline, lack of meaningful pipeline, . Can we expect a dividend increase?NLongby VellefauxDec 9, 2023114
Is PFE in that reversal zone?I'm not the biggest fan of PFE either, but with 25 analysts thinking about Buy with target between 75 and 32, has PFE come down far enough? Dividends. With the events of the next year coming up I may wait for a dip and put my toe in the water.NLongby bfallsDec 8, 2023110
Pfizer Daily ChartPfizer Daily Chart for Sunday Charting 12/3. Boxes and Downward channel. Failed a punchback after getting up to box above it then dumped after it broke cost basis of bottom box.NShortby jtboesen2022Dec 2, 20230
Pfizer Drops After Pulling Obesity-Drug Study Following PatientPfizer will retool its obesity drug efforts, but the delay is a blow to the group's ambitions to challenge Novo Nordisk and Lilly in the fast-developing space. Pfizer (NYSE: PFE) - shares slumped Friday after the drugmaker said it would not advance a study of its two-dose obesity treatment, following a high level of side effects in patients involved in the Phase II trial. Pfizer said it would instead focus on a single-dose option. Trials of its danuglipron treated showed good results in weight loss but induced vomiting and nausea in patients, which led to what it called "high discontinuation rates" compared with those taking a placebo. Pfizer's Mikael Dolsten, president of worldwide research and development, in late October called the danuglipron study "our main opportunity here for getting data to review for obesity, in fact, to diabetes" in a call with investors. For Pfizer, a Setback in Weight-loss Market The decision marks a significant setback in Pfizer's ambitions to enter the weight-loss drug market, which is currently dominated by Novo Nordisk's Wegovy. Pfizer rival Eli Lilly (LLY) - Get Free Report last month also won approval for its own weight-loss treatment, Zepbound, from the Food and Drug Administration. At last check Pfizer stock was trading off 4.7% just above $28.91 That's a bit more than half its 52-week high near $55, set in mid-December 2022. Pfizer in October slashed its full-year sales and profit forecasts amid a slump in demand for covid treatments, It told investors it would write off around $4.6 billion in inventories of Paxlovid, its oral covid treatment, while taking a further $5.5 billion noncash charge against its third-quarter earnings. Price Momentum PFE is trading near the bottom of its 52-week range and below its 200-day simple moving average. What does this mean? Investors have been pushing the share price lower, and the stock still appears to have downward momentum. This is a negative sign for the stock's future value.NShortby DEXWireNewsDec 2, 20233
BULL WITH HORNS This is bull .. chart readers know what I am talking about.. load up traders.. lets go 40 with a SPIKE..NLongby MONEYMENOWNov 30, 20230
Pfizer: Big Pharma struggles in the post-COVID timesPfizer Inc. shares have reached their lowest levels since March 2020, during the height of the coronavirus pandemic. Since the beginning of 2023, the issuer's securities have declined due to reduced revenue from drug and COVID-19 vaccine sales. However, Pfizer's potential is not exhausted, as the company intends to introduce a new drug called Danuglipron to combat excess weight in the coming weeks. So today, let's look at the Pfizer Inc (NYSE: PFE) stock chart. On the D1 timeframe, support formed at 28.93, and resistance moved to 31.39. Quotes consolidated above the crucial level of 30.14. On the H1 timeframe, if there is a rebound from the 30.14 level, the target for a price increase can be placed at 33.98. In the medium term, the price could potentially reach 40.15. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67.85% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.Nby RoboMarketsNov 29, 20230
PFE may retest COVID lowshi traders PFE has been in a downtrend It looks cheap now, but the downtrend is still valid and we expect the retest of COVID lows (March 2020). If it happens, most likely PFE will bounce from there . Entry, stop loss and target are shown on the chart Do you agree?NLongby vf_investmentNov 27, 2023115
Pfizer $PFE improves its Momentum with a MACD oscillator breakupPfizer is improving relentless its momentum in last days . MACD oscillator is breaking up its downward pressure line, with accumulation on OBV. So.. Swing Trading Long this undervalued gem is a wise option for trader or investors. Have a great day..NLongby jordiquincocesNov 26, 20230
Swing Trading Long Pfizer Inc. on NYSE $PFESwing Trading Long PFE on hidden accumulation in OBV oscillator. TA is forming what could be an Inverted Hammer bottom pattern on oversold conditions. NLongby jordiquincocesUpdated Nov 26, 20230
PFE at the 200 sma on monthly After a 52%+ pull back in the last year, you can look at this chart and pretty easily determine your best case scenario and your worst case. A LOT of selling months in a row, leading up to a doji so far in Nov... NLongby ReallifetradingNov 21, 20232
PFE POSSIBLE SCENARIOPfizer approaching a very critical support(the yellow line at around 26.45) where bulls need to step-up. Losing this support could possibly mean more downside movement for the giant pharma stock. If the price just deviates below support. A potential long set-up is quite juicy for me. NLongby BlaircatsNov 14, 2023115
PFE Found Support going up.PFE Found March 2020 Support - going up. Selling Climax followed by a Double Bottom. Experimental trade - missing significant Accumulation. Hopefully leads to Mark Up. NLongby jforex78Nov 13, 20231
PFIZER - Weekly - TIME TO BUY?PFIZER - Weekly - TIME TO BUY? These are my keylevels on weekly time frame , the price its almost on monthly support where i will add some aditional shares on my portfolioNLongby sfc95Nov 13, 20231
Pfizer long-term movement after a deep correction - risky paperH i, I looked at Pfizer's chart and it looks like this deep correction won't stop until the $30 zone. The fact that side effects have developed worldwide due to the Covid vaccine and many people have filed lawsuits against pharmaceutical companies probably also plays a role in this deep decline. There is a lot of money in the pharmaceutical industry, so I think that the companies will have plenty of money to cover possible legal costs. And since in several countries they have signed papers that they request the vaccination on their own responsibility, the exclusion of liability will be justified in many cases. The $30 zone seems like a perfect turning point because I see it as a strong level. If the $30 zone holds, we will most likely look at the $40 zone, which also coincides with an important Fibonacci level. Do not forget. This does not constitute investment advice. Do your own research before entering a position. Regards In extreme cases, the $27 level is also possible.Nby XOX_XOXUpdated Nov 4, 20231110
PFE Pfizer Options Ahead of EarningsAnalyzing the options chain and the chart patterns of PFE Pfizer prior to the earnings report this week, I would consider purchasing the 30usd strike price at the money Calls with an expiration date of 2023-11-10, for a premium of approximately $0.91. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it. NLongby TopgOptionsUpdated Nov 3, 20235
Let's Buy Some Phizer!Analysis of Pfizer Inc. (PFE) on NYSE (Monthly Timeframe) The provided chart exhibits the long-term price movement of Pfizer Inc. on the New York Stock Exchange, with data captured on a monthly timeframe, extending over a period from roughly 2006 to the current date. Observations: The PFE stock observed a substantial rally that commenced around 2018, propelling the price to reach an apex slightly above $61.71. Post its peak, a pronounced correction is evident, causing the stock to retreat to its current price region near $31.16. The Fibonacci retracement levels on the chart highlight pivotal zones of potential resistance and support. As of now, the stock is oscillating near the 0.5 retracement level ($34.09). Over the longer term, the stock has been largely range-bound, especially between 2006 to 2018, indicating regions of historical resistance and support. The Relative Strength Index (RSI) and the Stochastic Oscillator reflect a bearish momentum with the potential for some upside, considering they are in or approaching the oversold region. Short to Mid-Term Targets: Immediate support appears to be at the 0.618 Fibonacci level ($29.75). Should the price maintain above this level, the immediate resistance to watch would be the 0.5 level ($34.09). Beyond this, the 0.382 level at approximately $42.37 presents the next significant resistance. Long-Term Perspective: Should the stock regain bullish momentum, overcoming the historical peak around $61.71 would be crucial for setting the stage for potential new highs. Conversely, if the downtrend continues and breaches the 0.618 level ($29.75), the stock may seek support around its previous low regions, notably close to $20. Conclusion: Investors are encouraged to pay heed to the evolving price dynamics and corroborate the technical indications with other relevant market news or potential catalysts. As always, considering protective measures like setting a stop-loss can aid in risk management.NLongby kargaaNov 3, 20232
PFIZER Simulation Max Pain +/- 30%max pain running 500 simulations on weekly chart is a +/- 30% move in PFE for the end of the year. earnings could be spicy on this one.NLongby zimeaBlueOct 25, 20232